[go: up one dir, main page]

WO2017141204A3 - Biguanide grafted / modified biopolymers as drug delivery vehicles - Google Patents

Biguanide grafted / modified biopolymers as drug delivery vehicles Download PDF

Info

Publication number
WO2017141204A3
WO2017141204A3 PCT/IB2017/050909 IB2017050909W WO2017141204A3 WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3 IB 2017050909 W IB2017050909 W IB 2017050909W WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3
Authority
WO
WIPO (PCT)
Prior art keywords
entry
promoting
agent
relates
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/050909
Other languages
French (fr)
Other versions
WO2017141204A2 (en
Inventor
Kantaraja CHINDERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017141204A2 publication Critical patent/WO2017141204A2/en
Publication of WO2017141204A3 publication Critical patent/WO2017141204A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is related to the compounds and methods having entry promoting (broadly referred as drug delivery) properties. It particularly relates to entry promoting agents for delivery of proteins, polypeptides and analogues; nucleic acids and analogues; small molecules (often referred to as drugs including antimicrobials) with applications in research or medicinal/therapeutic use. More specifically it relates to existing biodegradable natural polymers or proteins or polypeptides or peptides or synthetic biopolymers decorated with biguanidine. It also relates to the method of synthesis/modification of biomolecules with biguanidine. Further aspect of the invention relates to the composition and method for entry promoting (delivery) of therapeutics or prophylactics or imaging agents or agents used in research or therapy. The method for promoting entry of an agent (introduced agent) into a eukaryotic or prokaryotic cell, the method comprising the step of exposing the cell to the introduced agent in the presence of an entry-promoting agent, wherein the entry-promoting agent comprises a linear and/or branched or dendrimeric, natural (carbohydrates or protein, polypeptides or peptides or polyamines), synthetic or semisynthetic polymer (amine bearing polymers) having a substituted biguanidine moieties (0.01 - 100%).
PCT/IB2017/050909 2016-02-17 2017-02-17 Biguanide grafted / modified biopolymers as drug delivery vehicles Ceased WO2017141204A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641005523 2016-02-17
IN201641005523 2016-02-17

Publications (2)

Publication Number Publication Date
WO2017141204A2 WO2017141204A2 (en) 2017-08-24
WO2017141204A3 true WO2017141204A3 (en) 2017-09-28

Family

ID=59624833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/050909 Ceased WO2017141204A2 (en) 2016-02-17 2017-02-17 Biguanide grafted / modified biopolymers as drug delivery vehicles

Country Status (1)

Country Link
WO (1) WO2017141204A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873541A4 (en) * 2018-10-30 2022-08-31 Ohio State Innovation Foundation Ph-activated nanoparticles
KR102371859B1 (en) * 2020-06-12 2022-03-07 연세대학교 산학협력단 A contrast agent for chemical exchange saturation transfer magnetic resonance imaging, and a chemical exchange saturation transfer magnetic resonance imaging method using the same
CN113930454A (en) * 2021-11-26 2022-01-14 南通大学 Application of Chitosan-Polymetformin as Gene Transfection Reagent
CN114478834B (en) * 2022-02-28 2023-08-08 江南大学 A kind of guanidine hyaluronic acid antibacterial polymer and its preparation method and application
CN114561046B (en) * 2022-02-28 2023-10-27 江南大学 A kind of guanidine-based hyaluronic acid type antibacterial hydrogel and its preparation method and application
EP4525827A1 (en) * 2022-04-24 2025-03-26 Peptomer Therapeutics Private Limited Synthetic cationic peptidomimetics, their derivatives and preparation thereof along with compositions for various medical applications
CN116637173B (en) * 2023-05-11 2024-03-22 南京医科大学附属口腔医院 Multi-guanidine antibacterial peptide oral microneedle
CN117384969A (en) * 2023-10-11 2024-01-12 上海市第六人民医院 A transfection reagent and its preparation method and application
CN119033929B (en) * 2023-10-18 2025-11-07 暨南大学 Functional modified hyperbranched spermine and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054123A1 (en) * 2011-10-11 2013-04-18 The Royal Veterinary College Methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054123A1 (en) * 2011-10-11 2013-04-18 The Royal Veterinary College Methods

Also Published As

Publication number Publication date
WO2017141204A2 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
WO2017141204A3 (en) Biguanide grafted / modified biopolymers as drug delivery vehicles
Zhang et al. Dynamic covalent polymers for biomedical applications
Wang et al. Recent advances in the fabrication, functionalization, and bioapplications of peptide hydrogels
Huang et al. Supramolecular hydrogels with reverse thermal gelation properties from (oligo) tyrosine containing block copolymers
Michels et al. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis
Xie et al. Calcium-ion-triggered co-assembly of peptide and polysaccharide into a hybrid hydrogel for drug delivery
MX364396B (en) Modified poly(beta-amino ester)s for drug delivery.
ATE312628T1 (en) CONTROLLED DEGRADABLE POLYMER BIOMOLECULE OR DRUG CARRIER AND METHOD FOR SYNTHESIS OF SUCH CARRIER
WO2007043048A3 (en) Self-assembled fmoc-ff hydrogels
BR112014014599A2 (en) alpha-aminoamidine polymers and their use
BR112015023168A8 (en) crystalline diketopiperazine composition, methods of producing diketopiperiperine particles, producing a composition and treating and using a crystalline diketopiperazine composition
EP2476695A3 (en) Peptide vaccines for cancers expressing tumor-associated antigens
MX2009011813A (en) Polyglutamic acids functionalized by cationic groups and hydrophobic groups and applications thereof, in particular therapeutic applications thereof.
Ho et al. Tunable surface charge enables the electrostatic adsorption-controlled release of neuroprotective peptides from a hydrogel–nanoparticle drug delivery system
Yishay‐Safranchik et al. Controlled release of doxorubicin and Smac‐derived pro‐apoptotic peptide from self‐assembled KLD‐based peptide hydrogels
FR2885130B1 (en) PROCESS FOR PREPARING POLYLYSIN DENDRIMERES GRAFTS
Chang et al. Preparation and characterization of a novel thermosensitive hydrogel based on chitosan and gelatin blends
Sun et al. Self-sorting microscale compartmentalized block copolypeptide hydrogels
Tian et al. Natural electroactive hydrogel from soy protein isolation
MX337358B (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof.
Hoque et al. Microgel-assisted delivery of adenosine to accelerate fracture healing
Clapacs et al. Coiled coil crosslinked alginate hydrogels dampen macrophage-driven inflammation
Wei et al. Degradable poly (amino acid) vesicles modulate DNA-induced inflammation after traumatic brain injury
Kong et al. Synthetic polypeptide bioadhesive based on cation− π interaction and secondary structure
Biscari et al. Antibacterial Broad‐Spectrum Dendritic/Gellan Gum Hybrid Hydrogels with Rapid Shape‐Forming and Self‐Healing for Wound Healing Application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17752778

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17752778

Country of ref document: EP

Kind code of ref document: A2